Skip to main content
Clinical Trials/NCT04153110
NCT04153110
Completed
Not Applicable

Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxias: a Randomized, Double-blind, Sham-controlled Trial Followed by an Open-label Phase

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1 site in 1 country61 target enrollmentDecember 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ataxia
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Enrollment
61
Locations
1
Primary Endpoint
Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Neurodegenerative cerebellar ataxias represent a group of disabling disorders which currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study followed by an open-label phase, the investigators will evaluate whether a repetition of two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS, after a three months interval, may further outlast clinical improvement in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

Detailed Description

Neurodegenerative cerebellar ataxias represent a heterogeneous group of disabling disorders in which progressive ataxia of gait, limb dysmetria, oculomotor deficits, dysarthria and kinetic tremor are the prominent clinical manifestations. Both the hereditary and sporadic forms usually present in young adulthood, and are characterized by atrophy of cerebellar or brainstem structures. Currently, cerebellar ataxia lack effective disease-modifying therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. The present randomized, double-blind, sham-controlled study followed by an open-label phase will investigate a repetition of two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS, after a three months interval, may further outlast clinical improvement in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term. In addition the investigators will evaluate if tDCS intervention might improve cerebellar cognitive-affective syndrome in patients with ataxia.

Registry
clinicaltrials.gov
Start Date
December 1, 2018
End Date
January 1, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Barbara Borroni

Professor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Eligibility Criteria

Inclusion Criteria

  • Patients with a cerebellar syndrome and quantifiable cerebellar atrophy

Exclusion Criteria

  • Severe head trauma in the past
  • History of seizures
  • History of ischemic stroke or hemorrhage
  • Pacemaker
  • Metal implants in the head/neck region
  • Severe comorbidity
  • Intake of illegal drugs
  • Pregnancy

Outcomes

Primary Outcomes

Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline

Time Frame: Baseline - 2 weeks

International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia).

Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline

Time Frame: Baseline - 2 weeks

Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).

Change in the Cerebellar cognitive affective syndrome (CCAS) Scale From Baseline

Time Frame: Baseline - 2 weeks

CCAS/Schmahmann syndrome scale: 120 point scale, yielding a total score of 0 (most severe cognitive impairment) to 120 (no cognitive impairment).

Secondary Outcomes

  • Change in the Short-Form Health Survey 36 (SF36) Score From Baseline(Baseline - 2 weeks - 3 month - 6 months - 9 months)
  • Change in the Cerebellar cognitive affective syndrome (CCAS) Scale From Baseline(Baseline - 2 weeks - 3 month - 6 months - 9 months)
  • Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline(Baseline - 2 weeks - 3 month - 6 months - 9 months)
  • Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline(Baseline - 2 weeks - 3 month - 6 months - 9 months)
  • Change in Cerebellar Brain Inhibition (CBI) Measurements From Baseline(Baseline - 2 weeks - 3 month - 6 months - 9 months)

Study Sites (1)

Loading locations...

Similar Trials